Aeglea BioTherapeutics Inc. is a clinical-stage biopharmaceutical company that is focused on developing innovative treatments for rare genetic diseases and cancer. The company was founded in 2013 and is headquartered in Austin, Texas.
Aeglea BioTherapeutics' mission is to develop and deliver transformative treatments for patients with rare genetic diseases and cancer. The company's solutions are designed to be highly targeted and effective, with a focus on improving outcomes and quality of life for patients.
One of Aeglea BioTherapeutics' key strengths is its expertise in amino acid metabolism. The company's products are based on the concept of depleting certain amino acids that are essential for the growth and survival of cancer cells and other diseases. By targeting specific amino acids, Aeglea BioTherapeutics' products can selectively kill cancer cells and improve outcomes for patients with rare genetic diseases.
Aeglea BioTherapeutics has a range of products in development, including enzyme replacement therapies, cancer treatments, and immune-oncology therapies. The company's lead product candidate is pegzilarginase, which is an enzyme replacement therapy that is being developed for the treatment of rare genetic diseases that affect the metabolism of the amino acid arginine.
Aeglea BioTherapeutics is also committed to sustainability and corporate responsibility. The company has a strong commitment to environmental stewardship and social responsibility, with a focus on reducing its carbon footprint and promoting social welfare.
Aeglea BioTherapeutics Inc. is a clinical-stage biopharmaceutical company that is focused on developing innovative treatments for rare genetic diseases and cancer. The company's expertise in amino acid metabolism, research and development capabilities, and commitment to sustainability and social responsibility make it a compelling option for investors seeking exposure to the biopharmaceutical industry. As the demand for innovative treatments for rare genetic diseases and cancer continues to grow, Aeglea BioTherapeutics is well-positioned to be a leader in the development of new and effective therapies.